← board
RVMDW
distress 3/10 · well-funded / low risk$9.79+11%today0% from 52w high
Revenue
pre-revenue
Liquidity
$1908M
Runway
1.8 yrs
Shares 1y
+14%
Price & events
+384.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+11.2%
1D
+9.0%
1W
+420.7%
1M
+420.7%
3M
—
6M
—
1Y
—
2Y
—
5Y
+384.7%
All
Overview
- Market Cap
- $2.08B
- Volume
- 4.32K
- 52 Week Range
- $1.79 – $9.79
- Total Shares
- 212.60M
- Float Shares
- 194.11M
- RVOL
- 1.46x
- Beta
- 1.38
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-06-24Form 144 | Revolution Medicines(RVMD.US) Officer Proposes to Sell 3.39 Million in Common Stocks - Moomoo
- 2026-06-17Revolution Medicines Inc (RVMDW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-06-17Revolution Medicines Inc (RVMDW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
- 2026-04-13Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial - CNBC
- 2026-02-14Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push - Yahoo Finance
- 2026-01-09Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle (RVMD) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.